Top

Published in:

Open Access 01-12-2022 | Breast Cancer | Research

Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry

Authors: Catherine Philippson, Samuel Larsen, Stéphane Simon, Christophe Vandekerkhove, Alex De Caluwe, Dirk Van Gestel, Marie Chintinne, Isabelle Veys, Filip De Neubourg, Danièle Noterman, Mirela Roman, Jean-Marie Nogaret, Antoine Desmet

Published in: Breast Cancer Research | Issue 1/2022

Abstract

Background

Intraoperative electron radiotherapy (IOERT) can be used to treat early breast cancer during the conservative surgery thus enabling shorter overall treatment times and reduced irradiation of organs at risk. We report on our first 996 patients enrolled prospectively in a registry trial.

Methods

At Jules Bordet Institute, from February 2010 onwards, patients underwent partial IOERT of the breast. Women with unifocal invasive ductal carcinoma, aged 40 years or older, with a clinical tumour size ≤ 20 mm and tumour-free sentinel lymph node (on frozen section and immunohistochemical analysis). A 21 Gy dose was prescribed on the 90% isodose line in the tumour bed with the energy of 6 to 12 MeV (Mobetron®-IntraOp Medical).

Results

Thirty-seven ipsilateral tumour relapses occurred. Sixteen of those were in the same breast quadrant. Sixty patients died, and among those, 12 deaths were due to breast cancer. With 71.9 months of median follow-up, the 5-year Kaplan–Meier estimate of local recurrence was 2.7%.

Conclusions

The rate of breast cancer local recurrence after IOERT is low and comparable to published results for IORT and APBI. IOERT is highly operator-dependent, and appropriate applicator sizing according to tumour size is critical. When used in a selected patient population, IOERT achieves a good balance between tumour control and late radiotherapy-mediated toxicity morbidity and mortality thanks to insignificant irradiation of organs at risk.

Available only for authorised users

Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–30. https://doi.org/10.1093/annonc/mdv298.CrossRefPubMed

Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2.CrossRefPubMed

Badakhshi H, Gruen A, Sehouli J, Budach V, Boehmer D. The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study. Cancer Med. 2013;2(5):712–7. https://doi.org/10.1002/cam4.114.CrossRefPubMedPubMedCentral

Gupta S, Rastogi K, Bhatnagar A, Singh D, Gupta K, Choudhary A. Compliance to radiotherapy: a tertiary care center experience. Indian J Cancer. 2018;55(2):166. https://doi.org/10.4103/ijc.ijc_517_17.CrossRefPubMed

Abe O, Abe R, Enomoto K, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106. https://doi.org/10.1016/S0140-6736(05)67887-7.CrossRef

Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20. https://doi.org/10.1056/NEJMoa0906260.CrossRefPubMed

Forrest AP, Stewart HJ, Everington D, et al. Randomized controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet. 1996;348(9029):708–13. https://doi.org/10.1016/S0140-6736(96)02133-2.CrossRefPubMed

Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328(22):1587–91. https://doi.org/10.1056/NEJM199306033282202.CrossRefPubMed

Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–26. https://doi.org/10.1016/S0140-6736(20)30932-6.CrossRefPubMedPubMedCentral

10.

Meattini I, Becherini C, Boersma L, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23(1):e21–31. https://doi.org/10.1016/S1470-2045(21)00539-8.CrossRefPubMed

11.

Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51(4):451–63. https://doi.org/10.1016/j.ejca.2014.12.013.CrossRefPubMed

12.

Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a ran. Lancet. 2016;387(10015):229–38. https://doi.org/10.1016/S0140-6736(15)00471-7.CrossRefPubMed

13.

Polgár C, Fodor J, Major T, Sulyok Z, Kásler M. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol. 2013;108(2):197–202. https://doi.org/10.1016/j.radonc.2013.05.008.CrossRefPubMed

14.

Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394(10215):2165–72. https://doi.org/10.1016/S0140-6736(19)32515-2.CrossRefPubMed

15.

Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048–60. https://doi.org/10.1016/S0140-6736(17)31145-5.CrossRefPubMedPubMedCentral

16.

Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. J Clin Oncol. 2020;38(35):4175–83. https://doi.org/10.1200/JCO.20.00650.CrossRefPubMed

17.

Korzets Y, Fyles A, Shepshelovich D, Amir E, Goldvaser H. Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;175(3):531–45. https://doi.org/10.1007/s10549-019-05209-9.CrossRefPubMed

18.

Vaidya JS, Bulsara M, Wenz F, et al. Reduced mortality with partial-breast irradiation for early breast cancer: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys. 2016;96(2):259–65. https://doi.org/10.1016/j.ijrobp.2016.05.008.CrossRefPubMed

19.

Simonetto C, Wollschläger D, Kundrát P, et al. Estimating long-term health risks after breast cancer radiotherapy: merging evidence from low and high doses. Radiat Environ Biophys. 2021;60(3):459. https://doi.org/10.1007/S00411-021-00924-8.CrossRefPubMedPubMedCentral

20.

Taylor C, Duane FK, Dodwell D, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641–9. https://doi.org/10.1200/JCO.2016.72.0722.CrossRefPubMedPubMedCentral

21.

Orecchia R, Veronesi U, Maisonneuve P, et al. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021;22(5):597–608. https://doi.org/10.1016/S1470-2045(21)00080-2.CrossRefPubMed

22.

Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269–77. https://doi.org/10.1016/S1470-2045(13)70497-2.CrossRefPubMed

23.

LENT Soma. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys. 1995;31(5):1049–91. https://doi.org/10.1016/0360-3016(95)90159-0.CrossRef

24.

Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81. https://doi.org/10.1016/S1053-4296(03)00031-6.CrossRefPubMed

25.

Gourgou-Bourgade S, Cameron D, Poortmans P, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol. 2015;26(5):873–9. https://doi.org/10.1093/ANNONC/MDV106.CrossRefPubMed

26.

Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(9):2206–23. https://doi.org/10.1093/ANNONC/MDT303.CrossRef

27.

Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet (London, England). 2002;359(9314):1309–10. https://doi.org/10.1016/s0140-6736(02)08272-7.CrossRefPubMed

28.

Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw. 2010;8(5):562–94. https://doi.org/10.6004/JNCCN.2010.0043.CrossRef

29.

Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–73. https://doi.org/10.1016/S1470-2045(14)71221-5.CrossRefPubMed

30.

Chesney TR, Yin JX, Rajaee N, et al. Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: a systematic review and meta-analysis. Radiother Oncol. 2017;123(1):1–9. https://doi.org/10.1016/j.radonc.2017.02.019.CrossRefPubMed

31.

Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7. https://doi.org/10.1200/JCO.2012.45.2615.CrossRefPubMedPubMedCentral

32.

Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(6):691–722. https://doi.org/10.6004/jnccn.2022.0030.CrossRef

33.

Philippson C, Simon S, Vandekerkhove C, et al. Early invasive cancer and partial intraoperative electron radiation therapy of the breast: experience of the Jules Bordet Institute. Int J Breast Cancer. 2014;2014:1–6. https://doi.org/10.1155/2014/627352.CrossRef

34.

Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155–64. https://doi.org/10.1016/S0140-6736(19)32514-0.CrossRefPubMedPubMedCentral

35.

Ott OJ, Strnad V, Hildebrandt G, et al. GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiother Oncol. 2016;120(1):119–23. https://doi.org/10.1016/J.RADONC.2016.06.019.CrossRefPubMed

36.

Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet (London, England). 2014;383(9917):603–13. https://doi.org/10.1016/S0140-6736(13)61950-9.CrossRefPubMed

37.

Vaidya JS, Bulsara M, Baum M, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ. 2020. https://doi.org/10.1136/BMJ.M2836.CrossRefPubMedPubMedCentral

38.

Vaidya JS, Wenz F, Bulsara M, et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technol Assess (Rockv). 2016;20(73):1–188. https://doi.org/10.3310/HTA20730.CrossRef

39.

Mejdahl MK, Wohlfahrt J, Holm M, et al. Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology. Breast Cancer Res Treat. 2020;182(1):229–38. https://doi.org/10.1007/S10549-020-05689-0.CrossRefPubMed

40.

Intra M, Luini A, Gatti G, et al. Surgical technique of intraoperative radiation therapy with electrons (ELIOT) in breast cancer: a lesson learned by over 1000 procedures. Surgery. 2006;140(3):467–71. https://doi.org/10.1016/J.SURG.2006.03.019.CrossRefPubMed

41.

Veronesi U, Gatti G, Luini A, et al. Intraoperative radiation therapy for breast cancer: technical notes. Breast J. 2003;9(2):106–12. https://doi.org/10.1046/J.1524-4741.2003.09208.X.CrossRefPubMed

42.

Orecchia R. Milan-Eliot randomized trial results: first analysis. Madrid: International Society of Intraoperative Radiation Therapy; 2008.

43.

Hensley FW. Present state and issues in IORT Physics. Radiat Oncol. 2017;12(1):1–30. https://doi.org/10.1186/S13014-016-0754-Z.CrossRef

44.

Leonardi MC, Maisonneuve P, Mastropasqua MG, et al. Accelerated partial breast irradiation with intraoperative electrons: using GEC-ESTRO recommendations as guidance for patient selection. Radiother Oncol. 2013;106(1):21–7. https://doi.org/10.1016/J.RADONC.2012.10.018.CrossRefPubMed

45.

Holland R, Connolly JL, Gelman R, et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol. 1990;8(1):113–8. https://doi.org/10.1200/JCO.1990.8.1.113.CrossRefPubMed

46.

Faverly DRG, Hendriks JHCL, Holland R, Faverly D. Breast carcinomas of limited extent frequency, radiologic-pathologic characteristics, and surgical margin requirements. Cancer. 2001;91(4):647–59. https://doi.org/10.1002/1097-0142(20010215)91:4%3c647::aid-cncr1053%3e3.0.co;2-z.CrossRefPubMed

47.

Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73–9. https://doi.org/10.1016/J.PRRO.2016.09.007/ATTACHMENT/44C2751F-DB2E-47DE-9180-685C894DD136/MMC1.PDF.CrossRefPubMed

48.

Strnad V, Krug D, Sedlmayer F, et al. DEGRO practical guideline for partial-breast irradiation. Strahlentherapie und Onkol. 2020;196(9):749–63. https://doi.org/10.1007/S00066-020-01613-Z/TABLES/3.CrossRef

49.

Goulding A, Asmar L, Wang Y, et al. Outcomes after accelerated partial breast irradiation in women with triple negative subtype and other “high risk” variables categorized as cautionary in the ASTRO guidelines. Front Oncol. 2021;11:428. https://doi.org/10.3389/FONC.2021.617439/BIBTEX.CrossRef

50.

Palubicka A, Jaworski R, Wekwejt M, et al. Surgical site infection after breast surgery: a retrospective analysis of 5-year postoperative data from a single center in Poland. Medicina (B Aires). 2019. https://doi.org/10.3390/MEDICINA55090512.CrossRef

51.

Gallagher M, Jones DJ, Bell-Syer SV. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD005360.PUB5/MEDIA/CDSR/CD005360/IMAGE_N/NCD005360-CMP-002-01.PNG.CrossRefPubMedPubMedCentral

52.

Polgár C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year resul. Lancet Oncol. 2017;18(2):259–68. https://doi.org/10.1016/S1470-2045(17)30011-6.CrossRefPubMed

53.

Vaidya JS, Bulsara M, Baum M, et al. New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer. Br J Cancer. 2021;125(3):380. https://doi.org/10.1038/S41416-021-01440-8.CrossRefPubMedPubMedCentral

Title: Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry
Authors: Catherine Philippson
Samuel Larsen
Stéphane Simon
Christophe Vandekerkhove
Alex De Caluwe
Dirk Van Gestel
Marie Chintinne
Isabelle Veys
Filip De Neubourg
Danièle Noterman
Mirela Roman
Jean-Marie Nogaret
Antoine Desmet
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Published in: Breast Cancer Research / Issue 1/2022
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-022-01582-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer

Androgen receptor function and targeted therapeutics across breast cancer subtypes

Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism

Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study

SRC kinase-mediated signaling pathways and targeted therapies in breast cancer

Microcalcifications, mammographic breast density, and risk of breast cancer: a cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer